アクセス数 : ?
ダウンロード数 : ?
ID 115032
タイトル別表記
Brodalumab in patients with GPP and PsE
著者
Yamasaki, K. Tohoku University
Nakagawa, H. The Jikei University
Ootaki, K. Kyowa Hakko Kirin
資料タイプ
学術雑誌論文
抄録
Background
A T‐helper (Th) cell subset Th17 preferentially produces interleukin (IL)‐17 and plays a pivotal role in the pathogenesis of psoriasis. However, the pathological roles of IL‐17 cascades in generalized pustular psoriasis (GPP) and psoriatic erythroderma (PsE) have not been well established.
Objectives
To evaluate the efficacy and safety of brodalumab, a human immunoglobulin G2 monoclonal antibody against human IL ‐17‐receptor A (IL‐17RA), in Japanese patients with GPP and PsE.
Methods
This was an open‐label, multicentre, long‐term phase III study in Japanese patients with rare and severe types of psoriasis. Patients received brodalumab 140 mg at day 1 and weeks 1 and 2, and then every 2 weeks until week 52. The primary endpoint was the Clinical Global Impression of Improvement (CGI). Safety evaluations included treatment‐emergent adverse events (AEs) and changes in laboratory parameters.
Results
A total of 12 patients with GPP and 18 with PsE were enrolled. Ten patients with GPP and 16 with PsE completed the study. At week 52 (last observation carried forward), CGI remission or improvement was achieved in 11 patients with GPP and 18 with PsE. The most commonly reported AE was nasopharyngitis (33·3%). Five serious AE s occurred during the study. However, none was considered treatment‐related.
Conclusions
Brodalumab significantly improved the symptoms of patients with GPP and PsE throughout the 52 weeks, and demonstrated favourable safety profiles without any new safety signals. Inhibition of IL‐17RA‐mediated signalling by brodalumab is expected to be a promising new treatment option for patients with GPP and PsE.
掲載誌名
British Journal of Dermatology
ISSN
13652133
出版者
British Association of Dermatologists|Wiley & Sons
176
3
開始ページ
741
終了ページ
751
発行日
2016-04-23
権利情報
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License(https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
EDB ID
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
医学系